Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Final Results Of a Phase II Study Of Lenalidomide In Combination With Rituximab For The Treatment Of Indolent Non Follicular Non Hodgkin Lymphoma

Stefano Sacchi, MD, Samantha Pozzi, MD, Marina Cesaretti, Luigi Marcheselli, MS, Gabriele Buda, MD, Antonio Lazzaro, MD, Luca Baldini, Francesco Di Raimondo, MD, Pellegrino Musto, MD, Alfonso Zaccaria, Giorgina Specchia, Umberto Vitolo, MD, Massimo Magagnoli, MD, Franco Silvestris, MD, Pier Paolo Fattori, MD, Patrizia Tosi, MD, Eliana Valentina Liardo, MD, Alessia Bari, MD, Angelo Michele Carella

Blood (2013) 122 (21): 4383.

https://doi.org/10.1182/blood.V122.21.4383.4383

Published: 2013

Journal Articles

Results of a Phase II Study of Lenalidomide in Combination with Rituximab for the Treatment of Indolent Non Follicular Non Hodgkin Lymphoma (NHL)

Stefano Sacchi, Samantha Pozzi, Marina Cesaretti, Luigi Marcheselli, Eliana Valentina Liardo, Gabriele Buda, Antonio Lazzaro, Luca Baldini, Francesco Di Raimondo, MD, Pellegrino Musto, Alfonso Zaccaria, Giorgina Specchia, Umberto Vitolo, Massimo Magagnoli, Franco Silvestris, Pier Paolo Fattori, Patrizia Tosi, Angelo Michele Carella

Blood (2012) 120 (21): 1645.

https://doi.org/10.1182/blood.V120.21.1645.1645

Published: 2012

Journal Articles

Systematic Review and Meta-Analysis of Randomized Controlled Trials of Erythropoietin in Multiple Myeloma.

Heloisa P. Soares, MD, Ambuj Kumar, MD, MPH, Franco Silvestris, MD, Benjamin Djulbegovic, MD, PhD

Blood (2004) 104 (11): 232.

https://doi.org/10.1182/blood.V104.11.232.232

Published: 2004

Journal Articles

Negative regulation of erythroblast maturation by Fas-L + /TRAIL + highly malignant plasma cells: a major pathogenetic mechanism of anemia in multiple myeloma

Franco Silvestris, Paola Cafforio, Marco Tucci, Franco Dammacco

Blood (2002) 99 (4): 1305–1313.

https://doi.org/10.1182/blood.V99.4.1305

Published: 2002

Journal Articles

Fas-L up-regulation by highly malignant myeloma plasma cells: role in the pathogenesis of anemia and disease progression

Franco Silvestris, Marco Tucci, Paola Cafforio, Franco Dammacco

Blood (2001) 97 (5): 1155–1164.

https://doi.org/10.1182/blood.V97.5.1155

Published: 2001

NARROW

Final Results Of a Phase II Study Of Lenalidomide In Combination With Rituximab For The Treatment Of Indolent Non Follicular Non Hodgkin Lymphoma

Results of a Phase II Study of Lenalidomide in Combination with Rituximab for the Treatment of Indolent Non Follicular Non Hodgkin Lymphoma (NHL)

Systematic Review and Meta-Analysis of Randomized Controlled Trials of Erythropoietin in Multiple Myeloma.

Negative regulation of erythroblast maturation by Fas-L + /TRAIL + highly malignant plasma cells: a major pathogenetic mechanism of anemia in multiple myeloma

Fas-L up-regulation by highly malignant myeloma plasma cells: role in the pathogenesis of anemia and disease progression

Email alerts

ASH Publications

American Society of Hematology

Final Results Of a Phase II Study Of Lenalidomide In Combination With Rituximab For The Treatment Of Indolent Non Follicular Non Hodgkin Lymphoma

Results of a Phase II Study of Lenalidomide in Combination with Rituximab for the Treatment of Indolent Non Follicular Non Hodgkin Lymphoma (NHL)

Systematic Review and Meta-Analysis of Randomized Controlled Trials of Erythropoietin in Multiple Myeloma.

Negative regulation of erythroblast maturation by Fas-L + /TRAIL + highly malignant plasma cells: a major pathogenetic mechanism of anemia in multiple myeloma

Fas-L up-regulation by highly malignant myeloma plasma cells: role in the pathogenesis of anemia and disease progression

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only